Nightingale's blood test can replace many routine blood tests currently used in healthcare (e.g. glucose), along with providing other blood biomarkers that can enhance disease risk prediction. In the long-term, Nightingale plans to provide better tools for clinicians, enabling preventive healthcare for chronic diseases, such as diabetes and cardiovascular disease.
"The only sustainable way to reduce the burden of chronic diseases is to invest in their prevention. The goal of this cooperative pilot with Coronaria is to prove Nightingale's technology's suitability for routine clinical use," says Nightingale Health's CEO Teemu Suna.
The pilot's cooperative partner Coronaria is one of Finland's largest providers of healthcare services.
"Coronaria aims to build a novel healthcare system in Finland that will benefit all of us, with patients receiving better care, personnel achieving more and society saving money. The emphasis in healthcare must be shifted to preventive and personalized care, especially for chronic disease treatments. We see Nightingale's blood analysis as an important tool to achieve this goal. As a result, we wanted to be the first to pilot the service in Finland", says Olli Karhi, member of the board of Cor Group.